ACA
PETX

Atlas Capital Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Atlas Capital Advisors’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-19,042
Closed -$68.6K – 688
2019
Q1 		$68.6K Buy
+19,042
New +$82.5K 0.02% 396

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Atlas Capital Advisors's PETX Position: Q2 2019 in Review

Atlas Capital Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 19,042 shares — an estimated $68.6K sold.

Atlas Capital Advisors first reported a position in PETX in Q1 2019 and held it in 1 quarter. The position peaked at $68.6K in Q1 2019. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Atlas Capital Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Atlas Capital Advisors sold 19,042 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $68.6K.
  • Atlas Capital Advisors first reported a position in Aratana Therapeutics, Inc. in Q1 2019 and held it in 1 quarter.
  • Atlas Capital Advisors's Aratana Therapeutics, Inc. position peaked at $68.6K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Atlas Capital Advisors's 13F filing for Q2 2019, filed 25 Jul 2019.